Control of pain initiation by endogenous cannabinoids

The potent analgesic effects of cannabis-like drugs^1-4 and the presence of CB1-type cannabinoid receptors in pain-processing areas of the brain and spinal cord^5,6 indicate that endogenous cannabinoids such as anandamide⁷ may contribute to the control of pain transmission within the central nervous system (CNS)⁸. Here we show that anandamide attenuates the pain behaviour produced by chemical damage to cutaneous tissue by interacting with CB1-like cannabinoid receptors located outside the CNS. Palmitylethanolamide (PEA), which is released together with anandamide from a common phospholipid precursor⁹, exerts a similar effect by activating peripheral CB2-like receptors. When administered together, the two compounds act synergistically, reducing pain responses 100-fold more potently than does each compound alone. Gas-chromatography/mass-spectrometry measurements indicate that the levels of anandamide and PEA in the skin are enough to cause a tonic activation of local cannabinoid receptors. In agreement with this possibility, the CB1 antagonist SR141716A and the CB2 antagonist SR144528 prolong and enhance the pain behaviour produced by tissue damage. These results indicate that peripheral CB1-like and CB2-like receptors participate in the intrinsic control of pain initiation and that locally generated anandamide and PA may mediate this effect.